Vitamin D 3 deficiency differentially affects functional and disease outcomes in the G93A mouse model of amyotrophic lateral sclerosis

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Solomon, Jesse A ^a,b   Gianforcaro, Alexandro ^a,b   Hamadeh, Mazen J ^a,b,c  

^a York University   (Canada)

^b YORK UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BRAIN SIZE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; GRIP STRENGTH; MALE; MOTOR PERFORMANCE; MOUSE; MUSCLE MASS; NONHUMAN; ONSET AGE; QUADRICEPS FEMORIS MUSCLE; SCORING SYSTEM; SEX DIFFERENCE; TIBIALIS ANTERIOR MUSCLE; VITAMIN D DEFICIENCY; VITAMIN INTAKE; ANIMAL; DISEASE MODEL; PATHOLOGY; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CHOLECALCIFEROL; DISEASE MODELS, ANIMAL; MALE; MICE; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VITAMIN D DEFICIENCY;

EID: 84455161566     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029354     Document Type: Article

References (100)

1. Nihei K, McKee AC, Kowall NW, (1993) Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol 86: 55-64.
2. Zang DW, Cheema SS, (2002) Degeneration of corticospinal and bulbospinal systems in the superoxide dismutase 1(G93A) (G1H) transgenic mouse model of familial amyotrophic lateral sclerosis. Neurosci Lett 332: 99-102.
3. Smith MC, (1960) Nerve Fibre Degeneration in the Brain in Amyotrophic Lateral Sclerosis. J Neurol Neurosur Ps 23: 269-282.
4. deCarvalho M, Matias T, Coelho F, Evangelista T, Pinto A, et al. (1996) Motor neuron disease presenting with respiratory failure. J Neurol Sci 139: 117-122.
5. Synofzik M, Fernandez-Santiago R, Maetzler W, Schols L, Andersen PM, (2010) The human G93A SOD1 phenotype closely resembles sporadic amyotrophic lateral sclerosis. J Neurol Neurosur Ps 81: 764-767.
6. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347: 1425-1431.
7. Miller RG, Mitchell JD, Lyon M, Moore DH, (2003) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 4: 191-206.
8. Bensimon G, Lacomblez L, Meininger V, (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330: 585-591.
9. Gurney ME, Pu HF, Chiu AY, Dalcanto MC, Polchow CY, et al. (1994) Motor-Neuron Degeneration in Mice That Express a Human Cu,Zn Superoxide-Dismutase Mutation. Science 264: 1772-1775.
10. Patel BP, Hamadeh MJ, (2009) Nutritional and exercise-based interventions in the treatment of amyotrophic lateral sclerosis. Clin Nutr 28: 604-617.
11. Hamadeh MJ, Rodriguez MC, Kaczor JJ, Tarnopolsky MA, (2005) Caloric restriction transiently improves motor performance but hastens clinical onset of disease in the Cu/Zn-superoxide dismutase mutant G93A mouse. Muscle Nerve 31: 214-220.
12. Hamadeh MJ, Tarnopolsky MA, (2006) Transient caloric restriction in early adulthood hastens disease endpoint in male, but not female, Cu/Zn-sod mutant G93A mice. Muscle Nerve 34: 709-719.
13. Patel BP, Safdar A, Raha S, Tarnopolsky MA, Hamadeh MJ, (2010) Caloric restriction shortens lifespan through an increase in lipid peroxidation, inflammation and apoptosis in the G93A mouse, an animal model of ALS. PLoS ONE 5: e9386.
14. Godar DE, Landry RJ, Lucas AD, (2009) Increased UVA exposures and decreased cutaneous Vitamin D(3) levels may be responsible for the increasing incidence of melanoma. Med Hypotheses 72: 434-443.
15. Holick MF, Chen TC, (2008) Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87: 1080S-1086S.
16. Nowson CA, Margerison C, (2002) Vitamin D intake and vitamin D status of Australians. Med J Aust 177: 149-152.
17. Holick MF, MacLaughlin JA, Doppelt SH, (1981) Regulation of cutaneous previtamin D3 photosynthesis in man: skin pigment is not an essential regulator. Science 211: 590-593.
18. Holick MF, (2006) Vitamin D. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, editors. Modern Nutrition in Health and Disease. 10 ed: Lippincott Williams & Wilkins pp. 376-395.
19. Gozdzik A, Barta JL, Weir A, Cole DE, Vieth R, et al. (2010) Serum 25-hydroxyvitamin D concentrations fluctuate seasonally in young adults of diverse ancestry living in Toronto. J Nutr 140: 2213-2220.
20. Nagpal S, Na S, Rathnachalam R, (2005) Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26: 662-687.
21. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ, (2005) Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 29: 21-30.
22. Prufer K, Veenstra TD, Jirikowski GF, Kumar R, (1999) Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord. J Chem Neuroanat 16: 135-145.
23. Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU, (2008) Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 149: 558-564.
24. Segersten U, Holm2 PK, Björklund P, Hessman O, Nordgren H, et al. (2005) 25-Hydroxyvitamin D3 1α-hydroxylase expression in breast cancer and use of non-1α-hydroxylated vitamin D analogue. Breast Cancer Res 7: R980-R986.
25. Bland R, Markovic D, Hills CE, Hughes SV, Chan SL, et al. (2004) Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol 89-90: 121-125.
26. Feldman D, Mccain TA, Hirst MA, Chen TL, Colston KW, (1979) Characterization of a Cytoplasmic Receptor-Like Binder for "1-Alpha,25-Dihydroxycholecalciferol in Rat Intestinal-Mucosa. J Biol Chem 254: 378-384.
27. Bischoff-Ferrari HA, Borchers M, Gudat F, Durmuller U, Stahelin HB, et al. (2004) Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 19: 265-269.
28. Wang YJ, DeLuca HF, (2011) Is the Vitamin D Receptor Found in Muscle? Endocrinology 152: 354-363.
29. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, et al. (2001) Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 86: 888-894.
30. Spach KM, Hayes CE, (2005) Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 175: 4119-4126.
31. Zehnder D, Bland R, Walker EA, Bradwell AR, Howie AJ, et al. (1999) Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in the human kidney. J Am Soc Nephrol 10: 2465-2473.
32. Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, et al. (2005) 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111: 1666-1671.
33. Taniura H, Ito M, Sanada N, Kuramoto N, Ohno Y, et al. (2006) Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J Neurosci Res 83: 1179-1189.
34. Hoeck AD, Pall ML, (2011) Will vitamin D supplementation ameliorate diseases characterized by chronic inflammation and fatigue? Med Hypotheses 76: 208-213.
35. Hamden K, Carreau S, Jamoussi K, Miladi S, Lajmi S, et al. (2009) 1Alpha,25 dihydroxyvitamin D3: therapeutic and preventive effects against oxidative stress, hepatic, pancreatic and renal injury in alloxan-induced diabetes in rats. J Nutr Sci Vitaminol (Tokyo) 55: 215-222.
36. Griffin MD, Xing NZ, Kumar R, (2003) Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr 23: 117-145.
37. Adorini L, (2005) Intervention in autoimmunity: The potential of vitamin D receptor agonists. Cell Immunol 233: 115-124.
38. Wang Y, Chiang YH, Su TP, Hayashi T, Morales M, et al. (2000) Vitamin D-3 attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 39: 873-880.
39. Junger H, Varon S, (1997) Neurotrophin-4 (NT-4) and glial cell line-derived neurotrophic factor (GDNF) promote the survival of corticospinal motor neurons of neonatal rats in vitro. Brain Res 762: 56-60.
40. Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, et al. (2008) Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 65: 1348-1352.
41. Dursun E, Gezen-Ak D, Yilmazer S, (2011) A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid- and preventing the amyloid- induced alterations by vitamin D in cortical neurons. J Alzheimers Dis 23: 207-219.
42. Cantorna MT, Munsick C, Bemiss C, Mahon BD, (2000) 1,25-dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 130: 2648-2652.
43. Zwerina K, Baum W, Axmann R, Heiland GR, Distler JH, et al. (2011) Vitamin D receptor regulates TNF-mediated arthritis. Ann Rheum Dis 70: 1122-1129.
44. Cantorna MT, Hayes CE, DeLuca HF, (1996) 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 93: 7861-7864.
45. Fernandes de Abreu DA, Ibrahim EC, Boucraut J, Khrestchatisky M, Feron F, (2010) Severity of experimental autoimmune encephalomyelitis is unexpectedly reduced in mice born to vitamin D-deficient mothers. J Steroid Biochem Mol Biol 121: 250-253.
46. Deluca HF, Plum LA, (2011) Vitamin D deficiency diminishes the severity and delays onset of experimental autoimmune encephalomyelitis. Arch Biochem Biophys 513: 140-143.
47. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM, (2001) Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358: 1500-1503.
48. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, et al. (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117: 503-511.
49. Reis JP, von Muhlen D, Michos ED, Miller ER 3rd, Appel LJ, et al. (2009) Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis 207: 585-590.
50. Pittas AG, Lau J, Hu FB, Dawson-Hughes B, (2007) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 92: 2017-2029.
51. Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, et al. (2007) Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 103: 708-711.
52. Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, et al. (2009) Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 30: 769-776.
53. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P, (2000) Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11: 847-852.
54. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, et al. (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108: 104-108.
55. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW, (1995) Prostate-Cancer and Prediagnostic Levels of Serum Vitamin-D Metabolites (Maryland, United-States). Cancer Causes Control 6: 235-239.
56. Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA, et al. (2006) Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidem Biomar 15: 1688-1695.
57. Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, et al. (2006) A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res 66: 10213-10219.
58. Gianforcaro A, Hamadeh MJ, Dietary vitamin D3 at 10 fold the adequate intake may attenuate disease severity in the transgenic G93A mouse model of ALS. FASEB J 2010 24: lb396 (abst.).
59. Reeves PG, Nielsen FH, Fahey GC, (1993) Ain-93 Purified Diets for Laboratory Rodents- Final Report of the American Institute of Nutrition Ad Hoc Writing Committee on the Reformulation of the Ain-76a Rodent Diet. J Nutr 123: 1939-1951.
60. [Anon], (1977) Report of American-Institute-of-Nutrition Ad Hoc Committee on Standards for Nutritional Studies. J Nutr 107: 1340-1348.
61. Sango K, McDonald MP, Crawley JN, Mack ML, Tifft CJ, et al. (1996) Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis. Nat Genet 14: 348-352.
62. Weydt P, Hong SY, Kliot M, Moller T, (2003) Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport 14: 1051-1054.
63. Solomon JA, Tarnopolsky MA, Hamadeh MJ, (2011) One universal common endpoint in mouse models of amyotrophic lateral sclerosis. PLoS ONE 6: e20582.
64. de Boland AR, Albornoz LE, Boland R, (1983) The effect of cholecalciferol in vivo on proteins and lipids of skeletal muscle from rachitic chicks. Calcif Tissue Int 35: 798-805.
65. Pleasure D, Wyszynski B, Sumner A, Schotland D, Feldmann B, et al. (1979) Skeletal-Muscle Calcium-Metabolism and Contractile-Force in Vitamin-D-Deficient Chicks. J Clin Invest 64: 1157-1167.
66. Curry OB, Basten JF, Francis MJ, Smith R, (1974) Calcium uptake by sarcoplasmic reticulum of muscle from vitamin D-deficient rabbits. Nature 249: 83-84.
67. Williams JH, Klug GA, (1995) Calcium Exchange Hypothesis of Skeletal-Muscle Fatigue- a Brief Review. Muscle Nerve 18: 421-434.
68. Gerdhem P, Ringsberg K, Obrant K, Akesson K, (2005) Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporos Int 16: 1425-1431.
69. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Hu FB, Zhang Y, et al. (2004) Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged & or = 60 y. Am J Clin Nutr 80: 752-758.
70. Verschueren SMP, Bogaerts A, Delecluse C, Claessens AL, Haentjens P, et al. (2011) The Effects of Whole-Body Vibration Training and Vitamin D Supplementation on Muscle Strength, Muscle Mass, and Bone Density in Institutionalized Elderly Women: A 6-Month Randomized, Controlled Trial. J Bone Miner Res 26: 42-49.
71. Stockton KA, Mengersen K, Paratz JD, Kandiah D, Bennell KL, (2011) Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis. Osteoporos Int 22: 859-871.
72. Atif F, Sayeed I, Ishrat T, Stein DG, (2009) Progesterone with Vitamin D Affords Better Neuroprotection against Excitotoxicity in Cultured Cortical Neurons than Progesterone Alone. Mol Med 15: 328-336.
73. Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, et al. (2001) Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci 21: 98-108.
74. Stuiver BT, Douma BRK, Bakker R, Nyakas C, Luiten PGM, (1996) In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: Combined therapy and temporal course of protection. Neurodegeneration 5: 153-159.
75. Brown J, Bianco JI, McGrath JJ, Eyles DW, (2003) 1,25-Dihydroxyvitamin D-3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett 343: 139-143.
76. Neveu I, Naveilhan P, Jehan F, Baudet C, Wion D, et al. (1994) 1,25-Dihydroxyvitamin D-3 Regulates the Synthesis of Nerve Growth-Factor in Primary Cultures of Glial-Cells. Molecular Brain Research 24: 70-76.
77. Lambiase A, Aloe L, Centofanti M, Parisi V, Mantelli F, et al. (2009) Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. Proc Natl Acad Sci U S A 106: 13469-13474.
78. Cohen RI, Marmur R, Norton WT, Mehler MF, Kessler JA, (1996) Nerve growth factor and neurotrophin-3 differentially regulate the proliferation and survival of developing rat brain oligodendrocytes. J Neurosci 16: 6433-6442.
79. Althaus HH, Kloppner S, Schmidt-Schultz T, Schwartz P, (1992) Nerve growth factor induces proliferation and enhances fiber regeneration in oligodendrocytes isolated from adult pig brain. Neurosci Lett 135: 219-223.
80. Chung J, Kubota H, Ozaki Y, Uda S, Kuroda S, (2010) Timing-dependent actions of NGF required for cell differentiation. PLoS ONE 5: e9011.
81. Fleet JC, Gliniak C, Zhang ZY, Xue YB, Smith KB, et al. (2008) Serum metabolite profiles and target tissue gene expression define the effect of cholecalciferol intake on calcium metabolism in rats and mice. J Nutr 138: 1114-1120.
82. Vieth R, Milojevic S, Peltekova V, (2000) Improved cholecalciferol nutrition in rats is noncalcemic, suppresses parathyroid hormone and increases responsiveness to 1, 25-dihydroxycholecalciferol. J Nutr 130: 578-584.
83. Hughes MR, Baylink DJ, Gonnerman WA, Toverud SU, Ramp WK, et al. (1977) Influence of dietary vitamin D3 on the circulating concentration of its active metabolites in the chick and rat. Endocrinology 100: 799-806.
84. Jones G, (2008) Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 88: 582s-586s.
85. Rowling MJ, Gliniak C, Welsh J, Fleet JC, (2007) High dietary vitamin D prevents hypocalcemia and osteomalacia in CYP27B1 knockout mice. J Nutr 137: 2608-2615.
86. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, et al. (2010) Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 11: 344-349.
87. Beers DR, Henkel JS, Zhao W, Wang J, Appel SH, (2008) CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A 105: 15558-15563.
88. Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, et al. (2008) T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci U S A 105: 17913-17918.
89. Zhang ZL, Ding XF, Tong J, Bing YL, (2011) Partial Rescue of the Phenotype in 1a-Hydroxylase Gene Knockout Mice by Vitamin D3 Injection. Endocr Res 36: 101-108.
90. Derave W, Van Den Bosch L, Lemmens G, Eijnde BO, Robberecht W, et al. (2003) Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment. Neurobiol Dis 13: 264-272.
91. Snow RJ, Turnbull J, da Silva S, Jiang F, Tarnopolsky MA, (2003) Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience 119: 661-667.
92. Mazzini L, Balzarini C, Colombo R, Mora G, Pastore I, et al. (2001) Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. J Neurol Sci 191: 139-144.
93. Pongratz D, (1999) The diagnostic process in ALS. J Neurol Sci 165: S10-S13.
94. Louwerse ES, Weverling GJ, Bossuyt PMM, Meyjes FEP, Dejong JMBV, (1995) Randomized, Double-Blind, Controlled Trial of Acetylcysteine in Amyotrophic-Lateral-Sclerosis. Arch Neurol 52: 559-564.
95. Tandan R, Bromberg MB, Forshew D, Fries TJ, Badger GJ, et al. (1996) A controlled trial of amino acid therapy in amyotrophic lateral sclerosis. 1. Clinical, functional, and maximum isometric torque data. Neurology 47: 1220-1226.
96. Yanagihara R, Garruto RM, Gajdusek DC, Tomita A, Uchikawa T, et al. (1984) Calcium and vitamin D metabolism in Guamanian Chamorros with amyotrophic lateral sclerosis and parkinsonism-dementia. Ann Neurol 15: 42-48.
97. Jaarsma D, Guchelaar HJ, Haasdijk E, de Jong JM, Holstege JC, (1998) The antioxidant N-acetylcysteine does not delay disease onset and death in a transgenic mouse model of amyotrophic lateral sclerosis. Ann Neurol 44: 293.
98. Poduslo JF, Whelan SL, Curran GL, Wengenack TM, (2000) Therapeutic benefit of polyamine-modified catalase as a scavenger of hydrogen peroxide and nitric oxide in familial amyotrophic lateral sclerosis transgenics. Ann Neurol 48: 943-947.
99. The Jackson Laboratory (2011) B6SJL-Tg(SOD1*G93A)dl1Gur/J. http://jaxmice.jax.org/strain/002300.html. Accessed July 11, 2011.
100. Birge SJ, Haddad JG, (1975) 25-hydroxycholecalciferol stimulation of muscle metabolism. J Clin Invest 56: 1100-1107.